V6M.F MindMaze Therapeutics Holding SA

Healthcare Biotechnology Frankfurt Exchange
0.1612 EUR
Close of Nov 12, 2026
0.1440 3.16
Market cap
EUR 2.03M
P/E
-
P/B
1.14x
ROE
-46.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2024.

Is V6M.F undervalued?

Graham number

The Graham number of MindMaze Therapeutics Holding SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

MindMaze Therapeutics Holding SA fundamental analysis

No fundamental analysis for MindMaze Therapeutics Holding SA yet.

MindMaze Therapeutics Holding SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About MindMaze Therapeutics Holding SA

MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outpatient and home settings; MindMotion Companion, an application that manages pres…

Full company profile